Newsroom

Sorted by: Latest
-

Powerful Medical Receives FDA De Novo Approval for PMcardio "Queen of Hearts," Its AI ECG Model for Detecting Acute Heart Attacks

NEW YORK--(BUSINESS WIRE)--Powerful Medical, a leader in AI-driven cardiovascular diagnostics, today announced that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for Queen of Hearts (ACS AI ECG Model). The AI-powered model is designed to identify ECG findings suggestive of urgent acute coronary syndrome (ACS), which can include ST-segment elevation myocardial infarction (STEMI) and STEMI equivalents, and urgently notify clinicians of suspected cases. Heart attack...
-

UK Debt Management Office UK Regulatory Announcement: Issue of Debt

LONDON--(BUSINESS WIRE)--    DMO-TAS041/3728/002         The Minster Building21 Mincing LaneLondonEC3R 7AG T 020 7862 6500F 020 7862 6509www.dmo.gov.uk           A122\26 15 September 2026   PRESS NOTICE   RESULT OF THE SALE BY TENDER OF UP TO £1250 MILLION OF 0½% TREASURY GILT 2029The United Kingdom Debt Management Office ("DMO") announces that the tender of up to £1,250 million of 0½% Treasury Gilt 2029 (ISIN Code: GB00BLPK7227) has been allocated as follows:(Note: all prices in this notice ar...
-

ChatGPT Ads startet in Europa – Adform ist Technologieplattformpartner

HAMBURG, Deutschland--(BUSINESS WIRE)--Marken und Agenturen buchen ChatGPT Ads ab sofort über Adform und messen sie gemeinsam mit ihren übrigen Kampagnen...
-

Genexine’s GX-BP1 (SOX2 bioPROTAC) Suppresses Tumor Regrowth despite Osimertinib and Dato-DXd Combination and Achieves 6/6 Complete Responses in Triple Combination

SEOUL, South Korea--(BUSINESS WIRE)--Genexine, Inc. (KOSDAQ: 095700) announced that Jaehyun Choi, Ph.D., CEO and Head of R&D, presented new preclinical data for GX-BP1, the company’s SOX2-targeting bioPROTAC, at the 2026 World Conference on Lung Cancer (WCLC) in Seoul on September 13. The mini oral presentation, titled ‘Lung-Targeted mRNA-LNP Delivery of SOX2 bioPROTAC: A Comprehensive Strategy for LUAD, LUSC, and SCLC in Monotherapy and Combination Settings’ highlighted the potential of GX...
-

Samenvatting: Axo Longevity haalt een overtekende startkapitaalronde van $5M op om Europa’s toonaangevend lidmaatschap voor preventieve gezondheidszorg uit te bouwen

LONDEN & MADRID--(BUSINESS WIRE)--Axo Longevity kondigde vandaag de afsluiting aan van een overtekende startkapitaalronde van $5M om zijn lidmaatschap voor preventieve gezondheidszorg in heel Europa uit te breiden. De ronde werd gesteund door MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital en NIAN Sports & Entertainment, samen met angel-investeerders waaronder Dr. Jorge Planas van Clinica Planas Barcelona en Daniel Kulle, voormalig v...
-

Axo Longevity lève 5 millions de dollars lors d’un cycle d’amorçage sursouscrit pour développer le premier programme d’adhésion en matière de santé préventive en Europe

LONDRES et MADRID--(BUSINESS WIRE)--Axo Longevity a annoncé aujourd’hui la clôture d’un cycle d’amorçage sursouscrit de 5 millions de dollars destiné à développer son programme d’adhésion en matière de santé préventive à travers l’Europe. Ce tour de table a été soutenu par MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital et NIAN Sports & Entertainment, ainsi que par des investisseurs providentiels, notamment le Dr Jorge Planas de la C...
-

Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership

LONDON & MADRID--(BUSINESS WIRE)--Axo Longevity Raises Oversubscribed $5M Seed Round to Build Europe’s Leading Preventive Health Membership...
-

Resumen: Axo Longevity recauda 5 millones de dólares en una ronda de financiación inicial con exceso de demanda para crear el servicio de salud preventiva por suscripción líder en Europa

LONDRES Y MADRID--(BUSINESS WIRE)--Axo Longevity ha anunciado hoy el cierre de una ronda de financiación inicial de 5 millones de dólares, que ha tenido una demanda superior a la oferta, con el fin de ampliar su programa de salud preventiva para socios de toda Europa. La ronda contó con la participación de MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital y NIAN Sports & Entertainment, junto con inversores ángeles como el Dr. Jorge Pla...
-

Axo Longevity schließt eine überzeichnete Startkapitalrunde in Höhe von 5 Millionen US-Dollar ab, um Europas führendes Mitgliedersystem für präventive Gesundheitsvorsorge aufzubauen

LONDON & MADRID--(BUSINESS WIRE)--Axo Longevity hat heute den Abschluss einer überzeichneten Startkapitalrunde in Höhe von 5 Millionen US-Dollar bekannt gegeben, um sein Mitgliedersystem für präventive Gesundheitsvorsorge in ganz Europa auszubauen. Die Finanzierungsrunde wurde von MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital sowie NIAN Sports & Entertainment unterstützt, ebenso wie von Angel-Investoren, zu denen Dr. Jorge Planas v...
-

Riassunto: Axo Longevity raccoglie 5 milioni di dollari in un round seed sottoscritto in eccesso per realizzare il principale servizio di abbonamento per la salute preventiva in Europa

LONDRA e MADRID--(BUSINESS WIRE)--Axo Longevity oggi ha annunciato la chiusura di un round di finanziamento seed da 5 milioni di dollari sottoscritto in eccesso per ampliare il suo servizio di abbonamento per la salute preventiva in tutta Europa. Il round è stato sostenuto da MS&AD Ventures, Izou Partners, LifeX Ventures, Everywhere Ventures, UNQ, 51 Ventures, Cistern Capital e NIAN Sports & Entertainment, assieme agli angel investor tra cui il Dr. Jorge Planas della Clinica Planas Barc...